Photosensitive occipital lobe epilepsy

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:166409OMIM:132100G40.5
Who is this for?
Show terms as
7Active trials12Specialists8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Photosensitive occipital lobe epilepsy is a rare form of epilepsy in which seizures originate from the occipital lobe of the brain and are triggered by visual stimuli such as flickering lights, patterns, or transitions between light and dark environments. This condition primarily affects the visual processing areas of the brain and is classified under reflex epilepsies. It typically begins in childhood or adolescence and is characterized by an abnormal photoparoxysmal response on electroencephalography (EEG) when exposed to intermittent photic stimulation. The hallmark symptoms include visual phenomena such as elementary visual hallucinations (colored circles, spots, or flashing lights), transient blindness or visual field deficits, eye pain, and forced eye deviation during seizures. These visual symptoms may remain localized to the occipital region or may spread to involve other brain areas, potentially leading to secondary generalized tonic-clonic seizures. Some patients also experience headache following seizures, which can sometimes lead to misdiagnosis as migraine with aura. Nausea and vomiting may accompany seizure episodes. Management of photosensitive occipital lobe epilepsy involves both lifestyle modifications and pharmacological treatment. Patients are advised to avoid known visual triggers, including flickering screens, strobe lights, and certain visual patterns. Wearing polarized or blue-tinted lenses may help reduce photosensitivity. Antiseizure medications such as valproate and levetiracetam are commonly used and are often effective in controlling seizures. The prognosis is generally favorable, with many patients achieving good seizure control, and some individuals may experience remission over time, particularly those with onset in childhood.

Also known as:

Inheritance

Multifactorial

Caused by a mix of several genes and environmental factors

Age of Onset

Childhood

Begins in childhood, roughly ages 1 to 12

Orphanet ↗OMIM ↗NORD ↗

FDA & Trial Timeline

10 events
Apr 2026A Randomized Placebo-procedure Controlled Trial of the Enhancor System (PULmonary Artery Denervation) to Evaluate Safety and Efficacy in Patients With Combined Pre- and Post-capillary Pulmonary Hypertension Associated With Left Heart Disease

Pulnovo Medical, Inc. — NA

TrialNOT YET RECRUITING
Feb 2026Feasibility of Modulating Cognitive Control in OCD

Dartmouth-Hitchcock Medical Center — NA

TrialNOT YET RECRUITING
Jan 2026How do Patients With Amnesia Acquire New Knowledge?

University Hospital, Toulouse — NA

TrialNOT YET RECRUITING
Jan 2026Mechanisms Of Orbitofrontal Stimulation in Depression

Subha Subramanian — NA

TrialNOT YET RECRUITING
Sep 2025The Role of POLE Mutation in High Risk Endometrial Cancer.

Far Eastern Memorial Hospital

TrialRECRUITING
Aug 2025Flexible Ureteroscopy With a Flexible and Navigable Suction Ureteral Access Sheath Versus Mini-Percutaneous Nephrolithotomy for 1-2 cm Lower Pole Kidney Stones

The First Affiliated Hospital of Guangzhou Medical University — NA

TrialRECRUITING
Jul 2025Vertical Soft Tissue Augmentation With Tent Pole Technique and Its Influence on Marginal Bone Loss Around Dental Implants

University of Santiago de Compostela — NA

TrialNOT YET RECRUITING
Mar 2025Steerable vs Conventional FANS for <2cm Lower Pole Stone Treatment: SCULPT Trial

The First Affiliated Hospital of Guangzhou Medical University — NA

TrialRECRUITING
Nov 2024Minimal Vitrectomy and ILM Flap with Sodium Hyaluronate Gel for MH

Jie Zhong — NA

TrialENROLLING BY INVITATION
May 2024The Effect of Different Body Positions and Channel Sheaths on RIRS

The First Affiliated Hospital of Guangzhou Medical University — NA

TrialRECRUITING

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

No FDA-approved treatments are currently listed for Photosensitive occipital lobe epilepsy.

7 clinical trialsare actively recruiting — trials can provide access to cutting-edge therapies.

View clinical trials →

Clinical Trials

7 recruitingView all trials with filters →
Phase 22 trials
Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
Phase 2
Actively Recruiting
PI: Kathy Han (University Health Network, Princess Margaret Hospi) · Sites: Anchorage, Alaska; Tucson, Arizona +98 more · Age: 1899 yrs
Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer
Phase 2
Active
PI: Panagiotis Konstantinopoulos, MD, PhD (Dana-Farber Cancer Institute) · Sites: Chicago, Illinois; Boston, Massachusetts +2 more · Age: 1899 yrs
N/A3 trials
Steerable vs Conventional FANS for <2cm Lower Pole Stone Treatment: SCULPT Trial
N/A
Actively Recruiting
PI: Guohua Zeng, M.D. (The First Affiliated Hospital of Guangzhou Medical) · Sites: Guangzhou, Guangdong · Age: 1875 yrs
Pole Walking Intervention in Retirement Communities
N/A
Actively Recruiting
PI: Saija A Kontulainen, PhD (Professor, College of Kinesiology, University of S) · Sites: Saskatoon, Saskatchewan
Flexible Ureteroscopy With a Flexible and Navigable Suction Ureteral Access Sheath Versus Mini-Percutaneous Nephrolithotomy for 1-2 cm Lower Pole Kidney Stones
N/A
Actively Recruiting
· Sites: Guangzhou, Guangdong · Age: 1875 yrs
Other2 trials
POLE-END REAL LIFE: Endometrial Cancer Early Stages I-II and Advanced Stages III and IV Evaluation of POLE as a Prognostic Factor. Participants Are Women >= 18 Years Old, With the Pole Mutation
Enrolling by Invitation
PI: GRAZIA ARTIOLI (AULSS2 MARCA TREVIGIANA) · Sites: Treviso, TV; Treviso, Veneto · Age: 1899 yrs
The Role of POLE Mutation in High Risk Endometrial Cancer.
Actively Recruiting
· Sites: Banqiao District, New Taipei

Specialists

12 foundView all specialists →
TY
T&#xfc;lay Y&#x131;lmaz
Specialist
1 Photosensitive occipital lobe epilepsy publication
BB
Bet&#xfc;l Baykan
Specialist
1 Photosensitive occipital lobe epilepsy publication
VD
Veysi Demirbilek
Specialist
1 Photosensitive occipital lobe epilepsy publication
NB
Nerses Bebek
Specialist
1 Photosensitive occipital lobe epilepsy publication
AE
Ay&#x15f;e Deniz Elmal&#x131;
Specialist
1 Photosensitive occipital lobe epilepsy publication
T&
Tuba Cerraho&#x11f;lu &#x15e;irin
Specialist
1 Photosensitive occipital lobe epilepsy publication
PP
Panagiotis Konstantinopoulos, MD, PhD
BOSTON, MA
Specialist
PI on 2 active trials
AM
Ahmad M Metwalley
Specialist
PI on 3 active trials
DR
David Ring
Specialist
PI on 1 active trial
HC
hüseyin cengiz
Specialist
PI on 1 active trial
TB
Tony Dhillon, Bsc,FRCP
Specialist
PI on 1 active trial
NG
Nicolle Almeida, Graduate
Specialist
PI on 1 active trial

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Photosensitive occipital lobe epilepsy.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Photosensitive occipital lobe epilepsyForum →

No community posts yet. Be the first to share your experience with Photosensitive occipital lobe epilepsy.

Start the conversation →

Latest news about Photosensitive occipital lobe epilepsy

Disease timeline:

New recruiting trial: The Role of POLE Mutation in High Risk Endometrial Cancer.

A new clinical trial is recruiting patients for Photosensitive occipital lobe epilepsy

New recruiting trial: Flexible Ureteroscopy With a Flexible and Navigable Suction Ureteral Access Sheath Versus Mini-Percutaneous Nephrolithotomy for 1-2 cm Lower Pole Kidney Stones

A new clinical trial is recruiting patients for Photosensitive occipital lobe epilepsy

New recruiting trial: Refining Adjuvant Treatment in Endometrial Cancer Based on Molecular Features

A new clinical trial is recruiting patients for Photosensitive occipital lobe epilepsy

New recruiting trial: Pole Walking Intervention in Retirement Communities

A new clinical trial is recruiting patients for Photosensitive occipital lobe epilepsy

New recruiting trial: Steerable vs Conventional FANS for <2cm Lower Pole Stone Treatment: SCULPT Trial

A new clinical trial is recruiting patients for Photosensitive occipital lobe epilepsy

New recruiting trial: The Effect of Different Body Positions and Channel Sheaths on RIRS

A new clinical trial is recruiting patients for Photosensitive occipital lobe epilepsy

New recruiting trial: Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER

A new clinical trial is recruiting patients for Photosensitive occipital lobe epilepsy

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Photosensitive occipital lobe epilepsy

What is Photosensitive occipital lobe epilepsy?

Photosensitive occipital lobe epilepsy is a rare form of epilepsy in which seizures originate from the occipital lobe of the brain and are triggered by visual stimuli such as flickering lights, patterns, or transitions between light and dark environments. This condition primarily affects the visual processing areas of the brain and is classified under reflex epilepsies. It typically begins in childhood or adolescence and is characterized by an abnormal photoparoxysmal response on electroencephalography (EEG) when exposed to intermittent photic stimulation. The hallmark symptoms include visual

How is Photosensitive occipital lobe epilepsy inherited?

Photosensitive occipital lobe epilepsy follows a multifactorial inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does Photosensitive occipital lobe epilepsy typically begin?

Typical onset of Photosensitive occipital lobe epilepsy is childhood. Age of onset can vary across affected individuals.

Are there clinical trials for Photosensitive occipital lobe epilepsy?

Yes — 7 recruiting clinical trials are currently listed for Photosensitive occipital lobe epilepsy on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.

Which specialists treat Photosensitive occipital lobe epilepsy?

12 specialists and care centers treating Photosensitive occipital lobe epilepsy are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.